{"schema_version":"secwatch.filing_event.v1","accession":"0001724521-24-000159","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.369502+00:00","generated_at":"2026-05-30T04:39:59.876354+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arcus Q3 net loss $92M; casdatifan shows 34% ORR, domvanalimab 36% risk reduction","bullets":["Net loss $92M vs $71M YoY; revenue $48M (up from $32M) on $41M license and development services.","Cash, equivalents and securities $1.1B, providing runway into mid-2027; year-end expected $950M-$985M.","Casdatifan 100mg cohort: 34% ORR (25% confirmed), 19% primary progression, median PFS not reached.","Domvanalimab+zimberelimab reduced risk of death by 36% (HR=0.64) vs zim in 1L NSCLC; median OS not reached.","Clinical collaboration with AstraZeneca to test casdatifan + volrustomig in IO-naive ccRCC."],"urls":{"canonical":"https://secwatch.observer/filing/0001724521-24-000159","json":"https://secwatch.observer/filing/0001724521-24-000159.json","markdown":"https://secwatch.observer/filing/0001724521-24-000159.md","text":"https://secwatch.observer/filing/0001724521-24-000159.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000159/0001724521-24-000159-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000159/rcus-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:39:59.876354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}